BRAF mutation and PD-L1 expression in melanoma: Comparison between multiple PD-L1 IHC clones and BRAF mutation evaluated by FDA-approved kits versus NGS

Submitted by Anonymous (not verified) on
Publication date
Year
2017
Subtitle
Abstract published in conjunction with the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO). J Clin Oncol 35, 2017 (suppl; abstr e21050)
External link
https://meetinglibrary.asco.org/record/149377/abstract